Factory Supply 99% API Dasatinib Powder CAS 863127-77-9 Dasatinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: TGY201904160702
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >98%
• Appearance: White to off- White Crystalline Powder
• Molecular Formula: C22h28cln7o3s
• MW: 488.01
• Certificate: ISO 9001, USP
• Shelf Life: 24 Months
• Storage: Cool Dry Area
• Grade: Pharmaceutical Grade
• CAS No.: 302962-49-8
• Sample: Avaliable
• Service: OEM
• MOQ: 10 Grams
• Assay: 98%Min, 99% HPLC
• Test Method: USP
• Einecs No.: 801-607-0
• Keyword: Dasatinib
• Transport Package: Boil Bag
• Specification: HPLC 99%
• Trademark: TGY
• Origin: Xi′an, Shaanxi, China (Mainland)
• HS Code: 29341000
• Production Capacity: 4000kg/Month

Product Description

Product Name	Dasatinib,302962-49-8
Synonyms	Anhydrous dasatinib BMS dasatinib Dasatinib Dasatinib dasatinib (anhydrous) Dasatinib anhydrous Dasatinibum
CAS No.	82640-04-8
Molecular Formula	C22H28ClN7O3S
Molecular Weight	488.01
EINECS No.	801-607-0
Melting Point	275-286°C
Water Solubility	DMSO: 28 mg/mL, soluble
Appearance	White to off-white crystalline powder
Purity	98%min
Quality Standard	Enterprise standard
Storage conditions	Store in a cool & dry place. Keep away from strong light and heat.
Packing	1kg/foil bag;25kg/drum
Shipment	EMS;DHL;FedEx;TNT;UPS
Delivery Time	4-7 Working Days
Payment Terms	T/T; Western Union; MoneyGram; Bitcoin

 

Dasatinib is a cancer medicine that slows the growth and spread of cancer cells in the body.

Dasatinib, previously known as BMS-354825, Dasatinib is an oral multi- BCR/Abl and Src family tyrosine
kinase inhibitor approved for first-line use in patients with chronic myelogenous leukemia (CML) and
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
 

Test Items	Standards	Results
Appearance	White to off-white powder	off-white powder
Identification	IR	Conforms
Water	3.0~5.0%	4.0%
Heavy metals	≤20ppm	Conforms
Related Substance	Single impurity<0.1%	0.06%
	Total Impurities<1.0%	0.18%
Purity	≥98.0%	99.82%
Residue on ignition	<0.1%	0.05%

Dasatinib is used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) when
other cancer treatments have not been effective.



For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid
leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with
Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior
therapy.